Maja Artandi, MD
Publication Details
-
Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
Hepatogastroenterology. 2001 May-Jun; (39): 783-9
Patients with advanced unresectable hepatobiliary carcinomas have a dismal prognosis. The efficacy of systemic chemotherapy in these patients is negligible and often, in particular in patients with hepatocellular carcinomas, the toxicity of chemotherapy outweighs the potential palliative effect of antineoplastic agents. Gemcitabine is a new anticancer agent with a mild toxicity profile, which has demonstrated antineoplastic activity in many solid tumors. Therefore we investigated the effect of gemcitabine in patients with advanced nonresectable hepatocellular and cholangiocellular carcinomas in a phase II study.
Help